Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690468 · ClinicalTrials.gov registry record · Phase 1
PTX-200 and Carboplatin in Ovarian Cancer
A Phase 1 study, sponsored by Prescient Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01690468: Clinical Trial Phase 1 study, sponsored by Prescient Therapeutics.
NCT01690468 is a Phase 1 study that was terminated before completion, run by Prescient Therapeutics. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01690468, a Phase 1 study, was terminated before completion, sponsored by Prescient Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Primary Outcome
To determine the maximum tolerated dose of TCN-PM when combined with carboplatin in a Phase I clinical trial of biomarker-selected women with platinum-resistant, recurrent or persistent epithelial ovarian, fallopian tube and primary peritoneal cancer (OVCA).
Interventions
- DRUG Carboplatin
- DRUG Triciribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Why NCT01690468 stopped before completion
NCT01690468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01690468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01690468 about?
NCT01690468 is a clinical study titled "PTX-200 and Carboplatin in Ovarian Cancer". The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
What is the current status of trial NCT01690468?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-09. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01690468?
The interventions under investigation include: Carboplatin (DRUG), Triciribine (DRUG).
Who is sponsoring clinical trial NCT01690468?
This trial is sponsored by Prescient Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01690468's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia